EGFR and neoplasm: Importantly, our data also indicate that the combination of CER-1236 with either a BTK or EGFR inhibitor did not result in toxicity to normal tissues, nor does it affect peripheral blood counts or clotting kinetics, indicating the selectivity of the anti-tumor immune response.